Ten years of cholinesterase inhibitors

International Journal of Geriatric Psychiatry

Volumn 24, Issue 5, 2009, Pages 437-442

  Rodda, Joanne ^a,b   Walker, Z ^a,b,c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b North Essex Partnership NHS Foundation Trust ^*  (United Kingdom)

^c St Margaret's Hospital   (United Kingdom)

Author keywords

Aging; Alzheimer's; Cholinesterase inhibitors; Dementia; NICE guidance

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ANOREXIA; AWARENESS; BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; COGNITION; DAILY LIFE ACTIVITY; DEMENTIA; DIARRHEA; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DIZZINESS; DRUG MECHANISM; DRUG WITHDRAWAL; EDITORIAL; HUMAN; MENTAL DISEASE; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NAUSEA; NEUROPROTECTION; PARKINSON DISEASE; PATIENT ATTITUDE; PRACTICE GUIDELINE; TREATMENT DURATION; VOMITING;

ALZHEIMER DISEASE; ATTITUDE TO HEALTH; CHOLINESTERASE INHIBITORS; GERIATRIC PSYCHIATRY; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 67649360182     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2165     Document Type: Editorial

References (29)

1. Akaike A. 2006. Preclinical evidence of neuroprotection by cholinesterase inhibitors. Alzheimer Dis Assoc Disord 20 (2 Suppl 1): S8-S11.
2. Ballard CG, Chalmers KA, Todd C, et al. 2007. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology 68(20): 1726-1729.
3. Banerjee S, Chan J. 2005. Organisation of old age psychiatry services. Psychiatry 4(2): 73-76.
4. Beier MT. 2007. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention. Pharmacother 27(3): 399-411.
5. Birks J. 2006. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1: CD005593.
6. Black SE, Doody R, Li H, et al. 2007. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 69(5): 459-469.
7. Courtney C, Farrell D, et al. 2004. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363(9427): 2105-2115.
8. Cummings JL, Back C. 1998. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 6 (2 Suppl 1): S64-S78.
9. Feldman HH, Ferris S,Winblad B, et al. 2007. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 6(6): 501-512.
10. Geldmacher DS, Provenzano G, McRae T, et al. 2003. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 51(7): 937-944.
11. Gill SS, Bronskill SE, Mamdani M, et al. 2004. Representation of patients with dementia in clinical trials of donepezil. Can J Clin Pharmacol 11(2): e274-e285.
12. Hansen RA, Gartlehner G, Lohr KN, Kaufer DI. 2007. Functional outcomes of drug treatment in Alzheimer's disease: a systematic review and meta-analysis. Drugs Aging 24(2): 155-167.
13. Howard RJ, Juszczak E, Ballard CG, et al. 2007. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 357(14): 1382-1392.
14. Huey ED, Putnam KT, Grafman J. 2006. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 66(1): 17-22.
15. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den BH. 2005. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 331(7512): 321-327.
16. Kavirajan H, Schneider LS. 2007. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a metaanalysis of randomised controlled trials. Lancet Neurol. 6: 782-792.
17. Lanctot KL, Herrmann N, Yau KK, et al. 2003. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a metaanalysis. CMAJ 169(6): 557-564.
18. Lindesay J, Marudkar M, van DE, Wilcock G. 2002. The second Leicester survey of memory clinics in the British Isles. Int J Geriatr Psychiatry 17(1): 41-47.
19. Lingler JH, Martire LM, Schulz R. 2005. Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis. J Am Geriatr Soc 53(6): 983-990.
20. Minger SL, Esiri MM, McDonald B, et al. 2000. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 55(10): 1460-1467.
21. Nakano S, Asada T, Matsuda H, et al. 2001. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med 42(10): 1f441-1445.
22. National Clinical Guidance Number 42. NICE-SCIE Clinical Guideline on supporting people with dementia and their carers in health and social care. 2007a.
23. National Clinical Guidance Number 42. NICE-SCIE Clinical Guideline on supporting people with dementia and their carers in health and social care. 2007b.
24. National Institute for Health and Clinical Excellence. TA 19 Alzheimer's disease - donepezil, rivastigmine and galantamine. 2001.
25. Nobili F, Vitali P, Canfora M, et al. 2002. Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol 113(8): 1241-1248.
26. Phillips RJ, Bosanquet N. 2006. Role of cholinesterase inhibitors in dementia care: NICE's economic analysis has limitations. BMJ 333(7568): 603.
27. Ritchie CW, Ames D, Clayton T, Lai R. 2004. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 12(4): 358-369.
28. Tune L, Tiseo PJ, Ieni J, et al. 2003. Donepezil HCI (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 11(2): 169-177.
29. Winblad B, Kilander L, Eriksson S, et al. 2006. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 367(9516): 1057-1065.